Argenica Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Key Metrics
PE ratio
-
PB ratio
5.18
Dividend yield
-
Beta
0.70
Market cap
$37.25M
Enterprise value
$26.70M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://argenica.com.au |
| Mailing address | 117 Broadway Unit 4 Nedlands WA 6009 Australia |
| Phone / Fax | 61 8 9329 3396 / |
Dividends
More: Argenica Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Argenica Therapeutics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.AGN dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Argenica Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Liz Dallimore B.Sc., M.B.A., Ph.D. | CEO, MD & Director | ||
| Ms. Emma Waldon | CFO & Company Secretary | 49 | |
| Prof. Bruno Philip Meloni | Chief Scientific Officer |
Profitability and management effectiveness
Profit margin
-223.12%
Operating margin
-1638.01%
Return on assets
-35.03%
Return on equity
-67.68%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Argenica Therapeutics is 37.25M and its enterprise value is 26.70M. The enterprise value to revenue ratio of AGN is 8.31. The enterprise value to EBITDA ratio of AGN is -.
The AGN's stocks Beta value is 0.70 making it 30% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Argenica Therapeutics (AGN)
Argenica Therapeutics (ASX:AGN) Frequently Asked Questions
1. What is Argenica Therapeutics's Stock Symbol?
Argenica Therapeutics trades on ASX under the ticker symbol "AGN".
2. What is Argenica Therapeutics's stock price today?
One share of AGN stock can currently be purchased for approximately $0.29.
3. How can I contact Argenica Therapeutics?
Argenica Therapeutics's mailing address is 117 Broadway Unit 4 Nedlands WA 6009 Australia. The company can be reached via phone at 61 8 9329 3396.
4. What is Argenica Therapeutics's official website?
The official website of Argenica Therapeutics is https://argenica.com.au.